- Health Topics
- Health Education
- Research
- Grants and Training
- News and Events
- About NHLBI
An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
WHAT: A team of researchers led by scientists from the Framingham Heart Study has discovered 31 new genetic markers it says are associated with blood pressure. The large-scale study provides new insight into the genetic underpinnings of high blood pressure and researchers say it could lead to better ways to treat the disease. Their study was published in Nature Genetics.
High blood pressure, or hypertension, is a major risk factor for heart disease, kidney disease, and early death. Researchers have known for years that high blood pressure often runs in families and that other factors also contribute to the condition, including high sodium intake, lack of exercise, obesity, and the use of certain prescription medicines. But researchers know little about the genetic markers—genes or short sequences of DNA—specifically associated with blood pressure.
In the current study, scientists obtained genetic data from more than 330,000 people from around the globe, including healthy individuals and those with hypertension. Using sophisticated analytical methods, the researchers identified 31 previously unknown markers linked to blood pressure. Some of the genetic factors also appear to be associated with diabetes and kidney disease, they say. Their findings may offer clues to potential strategies for treating hypertension and preventing its complications.
The research team was led by scientists from the Framingham Heart Study in collaboration with over 200 investigators from 80 organizations. The study was funded by multiple organizations, including the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH).
WHO: Daniel Levy, M.D., Director, Framingham Heart Study, NHLBI, is available to comment on the findings and implications of this research.
CONTACT: For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or nhlbi_news@nhlbi.nih.gov (link sends e-mail).
Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at http://www.nhlbi.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.